Role of Combination Immunotherapy in Metastatic Renal Cell C

Key opinion leaders in the field of renal cell carcinoma management discuss the advent of combination immunotherapy in patients with metastatic disease.

Related Keywords

, Optimizing Outcomes , Patients With , Translating Evidence , Clinical Practice , Metastatic Renal Cell , Renal Cell Carcinoma , Nrcc , Kidney Cancer , Metastatic Rcc , Metastatic Kidney Cancer , Advanced Rcc , Advanced Kidney Cancer , Intermediate Risk , Poor Risk , Ipi Nivo , Nivo Ipi , Nivolumab , Ipilimumab , Trio Therapy , Immune Checkpoint Inhibitors , Checkmate 214 , Novel Therapy , Combination Therapy , Overall Survival Data , Taos Data , Duration Of Response , Adverse Events , Drug Adverse Events , Quality Of Life , Rqol ,